Information  X 
Enter a valid email address

EPIC/TIDM matching '0QN1'

Date
Time Source
Company
Announcement
21 Aug 2018 6:00 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera to Report First Half-Year Financial Figures and Provide Corporate Update on September 4, 2018
05 Jul 2018 6:00 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera to Present Novel Data Highlighting the Clinical Relevance of Peak Expiratory Flow as Predictor of Disease Progression in Duchenne Muscular Dystrophy
22 Jun 2018 6:00 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) UK's MHRA renews Early Access to Medicines Scheme Scientific Opinion for Santhera's Raxone® (idebenone) in Duchenne Muscular Dystrophy
12 Jun 2018 6:00 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Submits NDA in South Korea for Raxone® for the Treatment of LHON
12 Apr 2018 12:30 pm GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera's Shareholders Approve all Board Proposals at Today's Annual General Meeting
05 Apr 2018 6:00 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Announces Successful Completion of First Clinical Trial with Omigapil in Patients with Congenital Muscular Dystrophy
20 Mar 2018 6:00 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Reports Solid Top-line Growth in 2017 and Reiterates its Strategy to Obtain Approval for Idebenone in Duchenne Muscular Dystrophy
05 Mar 2018 6:00 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Reports Outcome of Exploratory Trial with Idebenone in PPMS Conducted at the NIH
22 Feb 2018 6:00 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Completes Capital Increase to Settle Obtained License from Polyphor
15 Feb 2018 6:00 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Obtains Worldwide Exclusive License from Polyphor to Develop and Commercialize Clinical Stage Candidate for Cystic Fibrosis and Other Pulmonary Diseases
06 Feb 2018 6:11 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Launches U.S. Expanded Access Program with Idebenone for Patients with Duchenne Muscular Dystrophy (DMD)
29 Jan 2018 6:00 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Reports Preliminary Key Financial Figures for 2017 and Provides Corporate Update
26 Jan 2018 6:00 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Receives Negative CHMP Opinion on Appeal for Authorization of Raxone® in Duchenne Muscular Dystrophy
24 Jan 2018 12:35 pm GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Anticipates Receiving a Negative CHMP Opinion on Appeal for Marketing Authorization Application for Raxone® in Duchenne Muscular Dystrophy
19 Jan 2018 6:00 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Plans to Announce Regulatory Feedback for Raxone® in DMD and 2017 Preliminary Key Financial Figures
19 Dec 2017 6:00 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Launches "Take a Breath DMD" Respiratory Disease Awareness Campaign for patients with Duchenne Muscular Dystrophy
06 Dec 2017 6:00 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne Muscular Dystrophy Awareness Day
06 Nov 2017 7:37 pm GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Todd Bazemore Steps Down from Role as Chief Operating Officer of Santhera's US Subsidiary
23 Oct 2017 6:00 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) First International Consensus Statement on the Clinical and Therapeutic Management of LHON published in the Journal of Neuro-Ophthalmology
03 Oct 2017 6:00 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Presents Data and Hosts Symposium on Respiratory Function Decline in Duchenne Muscular Dystrophy at the World Muscle Society Congress
15 Sep 2017 6:00 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Receives Negative Opinion from the CHMP for its Marketing Authorization Application for Raxone® in DMD and Intends to Appeal this Opinion
11 Sep 2017 6:00 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) First Patients Enrolled in UK's Early Access to Medicines Scheme for Santhera's Raxone® in Duchenne Muscular Dystrophy (DMD)
05 Sep 2017 6:00 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Announces Financial Results for the First Half-Year 2017 and Reports Commercial and Development Progress
31 Aug 2017 6:00 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Announces Approval of Raxone® for LHON in Israel
28 Aug 2017 6:00 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera to Publish First Half-Year Report and Corporate Update on September 5, 2017
26 Jun 2015 6:00 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) CHMP recommends granting a marketing authorization for Santhera's Raxone® for the treatment of Leber's Hereditary Optic Neuropathy (LHON)
22 Jun 2015 6:00 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Appoints Chief Financial Officer
10 Jun 2015 6:00 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Update on Pre-NDA Meeting with FDA on Raxone®/Catena® in Duchenne Muscular Dystrophy (DMD)
11 May 2015 11:54 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera's Shareholders Approve all Board Proposals at Annual Shareholders' Meeting
21 Apr 2015 6:15 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera's Positive Phase III Trial (DELOS) in Patients with Duchenne Muscular Dystrophy Published in The Lancet
14 Apr 2015 6:15 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Reports 2014 Financial Results and Significant Progress in All Programs
09 Apr 2015 6:15 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera receives FDA Fast Track Designation for Raxone®/Catena® (idebenone) for theTreatment of Duchenne Muscular Dystrophy
11 Mar 2015 6:15 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Principal Investigator to Present Phase III Data on Idebenone in Duchenne Muscular Dystrophy (DMD) at the Annual Meeting of the American Academy of Neurology (AAN)
30 Jan 2015 6:15 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Extends Executive Management and Appoints Chief Commercial Officer
23 Jan 2015 6:15 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera reports preliminary key financial figures for 2014
25 Nov 2014 6:20 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera and Parent Project Muscular Dystrophy ...
26 Sep 2014 6:15 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera to Present Results from Phase III Stud...
09 Sep 2014 6:15 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Reports First Half 2014 Financial Resu...
15 Aug 2014 6:15 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Receives CHF 13.4 Million Through Sale...
17 Jul 2014 6:15 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Repositions Omigapil in Congenital Mus...
24 Jun 2014 6:15 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) ValuationLAB issues research report on Santhera
05 Jun 2014 6:15 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) European Medicines Agency Validates Santhera's ...
22 May 2014 6:15 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Reports Positive Outcome for Catena...
20 May 2014 11:39 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera's Shareholders Approve all Board Propo...
15 May 2014 6:15 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera to Present at the Bio€quity 2014 ...
13 May 2014 6:00 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Announces Successful Outcome of Phase ...
07 May 2014 6:15 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Files Marketing Authorization Applicat...
08 Apr 2014 6:00 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Reports Financial Figures for 2013 and...
04 Apr 2014 6:15 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera to Present Financial Figures for 2013 ...
19 Mar 2014 6:15 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Receives US Patent for Fipamezole in t...
04 Mar 2014 6:15 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Presents New Efficacy Data from an Exp...
27 Feb 2014 6:15 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Raises CHF 1 Million in Private Placem...
21 Jan 2014 6:15 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Temporary Authorization for Use Granted for San...
26 Nov 2013 6:15 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera's Phase III program with Catena®/...
30 Oct 2013 6:15 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Secures Up to CHF 10 Million in Equity...
03 Sep 2013 6:15 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Closes License-Back Deal with Takeda F...
30 Aug 2013 6:15 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Successfully Concludes Restructuring i...
11 Jul 2013 6:15 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Initiates Collaboration with the Europ...
06 Jun 2013 6:16 am GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Secures Exclusive Rights from NIH for ...
13 May 2013 1:07 pm GNW   Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera's Shareholders Support Business Contin...


Company Announcements Archive »

 
Headlines
Top categories

24-Sep-2019 07:00 AM

Economic Events - Today's Events

UK24/09/2019 11:00 CBI Industrial Order ExpectationsUS24/09/2019 14:00 HPI m/m24/09/2019 14:00 S&P/CS Composite-20 HPI y/y24/09/2019 15:00 Richmond Manufacturing Index24/09/2019 15:00 CB ...

Company finder

a d v e r t i s e m e n t